Suppr超能文献

在细针抽吸活检分类为滤泡性肿瘤可疑的患者中,甲状腺结节和血清中小核糖核酸的表达以区分滤泡性腺瘤和癌症:一项初步研究。

Expression of micro-ribonucleic acids in thyroid nodules and serum to discriminate between follicular adenoma and cancer in patients with a fine needle aspiration biopsy classified as suspicious for follicular neoplasm: A preliminary study.

机构信息

Department of Thoracic Surgery, Pulmonary Hospital, Zakopane, Poland.

Center for Medical Genomics OMICRON, Jagiellonian University Medical College, Kraków, Poland.

出版信息

Adv Clin Exp Med. 2023 Sep;32(9):997-1007. doi: 10.17219/acem/160003.

Abstract

BACKGROUND

Approximately 10% of thyroid nodules undergoing fine needle aspiration biopsy (FNAB) receive a suspicious for follicular neoplasm (SFN) classification. Currently, there is no diagnostic tool to preoperatively discriminate between follicular adenoma (FA) and thyroid cancer (TC), and most patients require surgery to exclude malignancy.

OBJECTIVES

To characterize the micro-ribonucleic acid (miRNA) signature of tumors assessed as SFN and define circulating miRNA patterns to distinguish FA from follicular cancer in patients with thyroid nodules biopsied using FNAB.

MATERIAL AND METHODS

The study included excised tumor and thyroid tissue samples from 80 consecutive patients collected by a pathologist in the operating theater. The miRNA was isolated from specimens at the Center for Medical Genomics OMICRON, and next-generation sequencing (NGS) was used to obtain target miRNAs. In addition, miRNA expression was detected in serum using polymerase chain reaction (PCR).

RESULTS

Well-differentiated thyroid cancer (WDTC) samples had significantly higher expression levels of hsa-miR-146b-5p (p = 0.030) and hsa-miR-146b-3p (p = 0.032), while the expression levels of hsa-miR-195-3p were significantly lower (p = 0.032) in WDTC samples compared to FA specimens. The serum of TC patients showed markedly higher expression of the unique miRNA hsa-miR-195-3p (p = 0.039).

CONCLUSIONS

The overexpression of hsa-miR-146b-5p and hsa-miR-146b-3p, and the downregulation of hsa-miR-195-3p expression could be used as biomarkers to distinguish FA from WDTC in patients with FNAB results classified as Bethesda tier IV. In addition, hsa-miR-195-3p could act as a serum biomarker for differentiating patients with FA from those with WDTC, and preoperative measurement of its expression would help avoid unnecessary surgeries. However, this concept needs further verification in a more substantial prospective study.

摘要

背景

约 10%接受细针穿刺活检 (FNAB) 的甲状腺结节被分类为滤泡性肿瘤可疑 (SFN)。目前,尚无术前鉴别滤泡性腺瘤 (FA) 和甲状腺癌 (TC) 的诊断工具,大多数患者需要手术排除恶性肿瘤。

目的

分析评估为 SFN 的肿瘤的微小核糖核酸 (miRNA) 特征,并定义循环 miRNA 模式,以区分 FNAB 活检甲状腺结节患者中的 FA 与滤泡癌。

材料和方法

研究纳入了 80 名连续患者的切除肿瘤和甲状腺组织样本,由手术室病理学家收集。miRNA 是从医学基因组学中心 OMICRON 的标本中分离出来的,使用下一代测序 (NGS) 获得靶 miRNA。此外,使用聚合酶链反应 (PCR) 检测血清中的 miRNA 表达。

结果

分化良好的甲状腺癌 (WDTC) 样本中 hsa-miR-146b-5p(p=0.030) 和 hsa-miR-146b-3p(p=0.032) 的表达水平明显更高,而 WDTC 样本中 hsa-miR-195-3p 的表达水平明显更低 (p=0.032)。TC 患者的血清中独特的 miRNA hsa-miR-195-3p 的表达明显更高 (p=0.039)。

结论

hsa-miR-146b-5p 和 hsa-miR-146b-3p 的过表达,以及 hsa-miR-195-3p 表达的下调,可作为 FNAB 结果为贝塞斯达分级 IV 的患者中区分 FA 与 WDTC 的生物标志物。此外,hsa-miR-195-3p 可作为区分 FA 与 WDTC 患者的血清生物标志物,术前测量其表达有助于避免不必要的手术。然而,这一概念需要在更大规模的前瞻性研究中进一步验证。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验